Sequential Treatment Use in Clinical Practice for U.S. Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Since the approval of pembrolizumab monotherapy in the platinum-refractory setting for R/M HNSCC in 2016 and the subsequent approval of pembrolizumab alone or in combination with chemotherapy in first-line (1L) in 2019, pembrolizumab-based therapy has become a standard of care. To better understand current real-world practice patterns, this study assessed the use of sequential systemic treatment from 1L to 2L for patients with R/M HNSCC.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: D. Zheng, C.M. Black, G.M. Hair, B. Bidadi, N. Lerman, L. Ai, A. Zion, L. Zou, W. Gao, G.J. Hanna Tags: 144 Source Type: research
More News: Biology | Cancer & Oncology | Carcinoma | Chemotherapy | HNSCC | Physics | Radiology | Skin Cancer | Squamous Cell Carcinoma | Study